US FDA grants breakthrough theraphy designation for Celladon's Mydicar to ... pharmabiz.com Celladon Corporation, a clinical-stage biotechnology company developing novel therapies for patients with heart failure and other diseases characterized by SERCA enzyme deficiencies, announced that its lead product candidate, MYDICAR, has been ... |
